-
Sector Analysis
Premature Labor (PL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Premature Labor (PL) Marketed and Pipeline Drugs Report Overview Premature/preterm labor (PL) is labor occurring after 20 and before 37 weeks gestation. Premature deliveries cause more than half of long-term morbidity and 75% of perinatal mortality. Premature labor is diagnosed primarily by history and symptoms. Symptoms of preterm labor include regular contractions before term gestational age associated with cervical change, pelvic pressure, menstrual-like cramps, watery vaginal discharge, and lower back pain. Although lower back pain is present in normal pregnancy as well,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-101 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-101 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Bladder Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Bladder Cancer Drug Details: Pembrolizumab (Keytruda) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Catequentinib Hydrochloride in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Catequentinib Hydrochloride in Metastatic Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Catequentinib Hydrochloride in Metastatic Pancreatic Cancer Drug Details: Catequentinib hydrochloride...
-
Company Profile
ObsEva SA – Company Profile
ObsEva SA (ObsEva) is a clinical-stage biopharmaceutical company that develops and commercializes drugs for women’s reproductive health and pregnancy. The company's product portfolio comprises pipeline products for controlling preterm labor by reducing inflammation, decreasing uterine contractions, and preventing cervical changes and membrane ruptures; for the treatment of pain in association with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women and to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to the...
Add to Basket -
Sector Analysis
Endometriosis Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030
The endometriosis market size across the 7MM was valued at $1.05 billion in 2020 and is expected to achieve a CAGR of more than 9% during 2020-2030. Women with endometriosis develop tissue that looks and acts like endometrial tissue outside of the uterus, usually on other reproductive organs inside the pelvis or in the abdominal cavity. Risk factors for endometriosis include a family history of endometriosis, early age of menarche, short menstrual cycles, long duration of menstrual flow, heavy bleeding...
-
Product Insights
Net Present Value Model: Ebopiprant
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Ebopiprant Drug Details Ebopiprant (OBE-022) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – linzagolix choline
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry linzagolix choline Drug Details Linzagolix (Yselty) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone...
-
Product Insights
Endometriosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis – Drugs In Development, 2022, provides an overview of the Endometriosis (Women's Health) pipeline landscape. Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins. Report...
-
Product Insights
Uterine Leiomyoma (Uterine Fibroids) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
Uterine leiomyoma (uterine fibroids) clinical trials market research report provides top line data relating to the clinical trials on uterine leiomyoma (uterine fibroids). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).